| UHC UMR Medical and Drug | Benlysta® (Belimumab) - Commercial Medical Benefit Drug Policy | 2025-12-01 |
| UHC UMR Medical and Drug | Evenity® (Romosozumab-Aqqg) - Commercial Medical Benefit Drug Policy | 2025-12-01 |
| UHC UMR Medical and Drug | Ophthalmologic Complement Inhibitors - Commercial Medical Benefit Drug Policy | 2025-12-01 |
| UHC UMR Medical and Drug | Rebyota® (Fecal Microbiota, Live-Jslm) - Commercial Medical Benefit Drug Policy | 2025-12-01 |
| UHC UMR Medical and Drug | Zolgensma® (Onasemnogene Abeparvovec-Xioi) - Commercial Medical Benefit Drug Policy | 2025-12-01 |
| UHC Surest Medical and Drug | Benlysta® (Belimumab) - Commercial Medical Benefit Drug Policy | 2025-12-01 |
| UHC Surest Medical and Drug | Evenity® (Romosozumab-Aqqg) - Commercial Medical Benefit Drug Policy | 2025-12-01 |
| UHC Surest Medical and Drug | Ophthalmologic Complement Inhibitors - Commercial Medical Benefit Drug Policy | 2025-12-01 |
| UHC Surest Medical and Drug | Rebyota® (Fecal Microbiota, Live-Jslm) - Commercial Medical Benefit Drug Policy | 2025-12-01 |
| UHC Surest Medical and Drug | Zolgensma® (Onasemnogene Abeparvovec-Xioi) - Commercial Medical Benefit Drug Policy | 2025-12-01 |